Inspire Medical Investors Urged to Act as Jan. 5 Lead‑Plaintiff Deadline Nears in Inspire V Securities Case
The lawsuit is pending in Minnesota federal court, centering on claims that Inspire concealed operational problems with the Inspire V rollout.
Overview
- Notices from Hagens Berman, Rosen Law Firm, The Schall Law Firm, DJS Law Group, The Gross Law Firm, and Faruqi & Faruqi invite INSP shareholders to seek lead‑plaintiff status by January 5, 2026.
- The putative class covers investors who purchased Inspire Medical shares between August 6, 2024 and August 4, 2025.
- Plaintiffs allege the company overstated demand and launch readiness for Inspire V while training, onboarding, IT and customer approval systems, and Medicare billing capabilities were not in place.
- Filings cite Inspire’s August 4, 2025 disclosures, a reduction of 2025 EPS guidance by more than 80%, and a roughly $42.04, 32% single‑day stock drop as the core investor harm.
- No class has been certified, and the case is proceeding in the U.S. District Court for the District of Minnesota under Sections 10(b) and 20(a) and SEC Rule 10b‑5.